News | November 05, 2024
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
CSPC will receive an upfront payment of $100 million from AstraZeneca
This is used to treat central diabetes insipidus and bedwetting
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Stable profits, low leverage to keep credit profiles comfortable
Subscribe To Our Newsletter & Stay Updated
